Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts

Fig. 1

Schematic experimental timeline of DMPM orthotopic model generation, administration of CpG-ODN1826, and sacrifice of mice. Orthotopic models were generated by injecting exponentially growing MesoII and STO cells into the peritoneum of SCID mice. The day after cell injection, mice were randomized to receive saline or CpG-ODN1826 (20 µg/mouse, qdx5/wx4w): CpG-ODN1826 treatment started 4 days (STO and MesoII early-stage tumors) or 11 days (STO late-stage tumors) after cell injection. MesoII cell-injected mice were sacrificed as ascites was evident; STO cell-injected mice were sacrificed the day after the last CpG-ODN1826 treatment

Back to article page